| Literature DB >> 19880441 |
Lugkana Mato1, Jintanaporn Wattanathorn, Supaporn Muchimapura, Terdthai Tongun, Nawanant Piyawatkul, Kwanchanok Yimtae, Panida Thanawirattananit, Bungorn Sripanidkulchai.
Abstract
Recently, oxidative stress has been reported to contribute an important role in the decline of physical function as age advances. Numerous antioxidants can improve both physical and psychological performances resulting in the increase of health-related quality of life (HQOL). Therefore, we hypothesized that Centella asiatica, a medicinal plant reputed for nerve tonic, strength improvement and antioxidant activity, could improve the physical performance and HQOL especially in the physical satisfaction aspect, of the healthy elderly volunteer. To test this hypothesis, a double-blind, placebo-controlled, randomized trial was performed. Eighty healthy elderly were randomly assigned to receive placebo or standardized extract of C. asiatica at doses of 250, 500 and 750 mg once daily for 90 days. The subjects were evaluated to establish baseline data of physical performance using 30-s chair stand test, hand grip test and 6-min walk test. The health-related quality of life was assessed using SF-36. These assessments were repeated every month throughout the 3-month experimental period using the aforementioned parameters. Moreover, 1 month after the cessation of C. asiatica treatment, all subjects were also evaluated using these parameters again. The results showed that after 2 months of treatment, C. asiatica at doses of 500 and 750 mg per day increased lower extremity strength assessed via the 30-s chair stand test. In addition, the higher doses of C. asiatica could improve the life satisfaction subscale within the physical function subscale. Therefore, the results from this study appear to support the traditional reputation of C. asiatica on strength improvement, especially in the lower extremities of the elderly. C. asiatica also possesses the potential to be a natural resource for vigor and strength increase, in healthy elderly persons. However, further research is essential.Entities:
Year: 2011 PMID: 19880441 PMCID: PMC3136695 DOI: 10.1093/ecam/nep177
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Baseline characteristic of subjects.
| Baseline data | Placebo | CA250 | CA500 | CA750 |
|---|---|---|---|---|
| Age (years) | 65.70 ± 4.88 | 64.60 ± 4.54 | 64.20 ± 5.11 | 66.75 ± 4.73 |
| Education (years) | 10.90 ± 5.93 | 11.70 ± 5.55 | 11.25 ± 5.32 | 11.60 ± 6.08 |
| Blood pressure (mmHg) | 120.75 ± 8.48/ 80.20 ± 6.35 | 116.40 ± 11.43/ 76.45 ± 7.04 | 119.90 ± 11.36/ 80.35 ± 7.62 | 121.80 ± 9.99 |
| 79.20 ± 6.12 | ||||
| Blood sugar | 94.75 ± 12.49 | 92.45 ± 5.89 | 93.20 ± 7.32 | 95.20 ± 12.40 |
| Body mass index | 24.54 ± 4.33 | 22.87 ± 3.24 | 23.25 ± 2.50 | 23.75 ± 3.03 |
Subjects were measured baseline characteristic. Data are presented as mean ± SD. P- and F-values were compared between groups (n = 20/group).
Effect of C. asiatica on physical fitness measured by 30-s chair stand test and 6-min walk test.
| Items | Pre-dose baseline score | Post-dose score | ||||
|---|---|---|---|---|---|---|
| 1 month | 2 month | 3 month | Delay | |||
| 30-s chair stand test (times) | 16.05 ± 2.72 | 16.10 ± 3.67 | ||||
| Placebo | 15.85 ± 2.87 | 15.65 ± 2.80 | 15.70 ± 2.99 |
|
| |
|
|
| |||||
| 20.35 ± 4.82a,∗∗ | 18.60 ± 5.96 | |||||
| CA250 | 16.85 ± 4.21 | 18.40 ± 4.07 | 18.35 ± 4.85 |
|
| |
|
|
| |||||
| 20.35 ± 3.66b,∗∗ | 17.30 ± 4.03 | |||||
| CA500 | 16.80 ± 4.36 | 17.75 ± 3.80 | 19.90 ± 4.10a,∗∗ |
|
| |
|
|
| |||||
| 21.00 ± 4.48b,∗∗∗ | 17.90 ± 5.93 | |||||
| CA750 | 16.80 ± 3.09 | 17.45 ± 3.53 | 18.55 ± 3.17a,∗ |
|
| |
|
|
| |||||
|
| ||||||
| 6 min walk test (meters) | 518.35 ± 59.62 | 510.55 ± 78.06 | ||||
| Placebo | 515.60 ± 42.18 | 509.45 ± 55.78 | 504.95 ± 57.32 |
|
| |
|
|
| |||||
| 535.60 ± 52.40 | 519.25 ± 81.86 | |||||
| CA250 | 517.60 ± 59.75 | 527.95 ± 42.34 | 524.25 ± 49.77 |
|
| |
|
|
| |||||
| 521.35 ± 66.20 | 512.00 ± 67.95 | |||||
| CA500 | 509.50 ± 57.38 | 517.00 ± 64.62 | 523.10 ± 67.8 |
|
| |
|
|
| |||||
| 524.75 ± 80.68 | 520.55 ± 87.65 | |||||
| CA750 | 511.75 ± 54.12 | 517.80 ± 75.67 | 529.05 ± 82.27 |
|
| |
|
|
| |||||
Subjects were measured physical fitness measured by 30-s chair stand test and 6-min walk test. Data are presented as mean ± SD. P- and F-values were compared between pre-dose baseline score and post-dose 1, 2, 3 month and 1 month after cessation of treatment (n = 20/group).a, b P-value <.01 and.001 compared with pre-dose baseline score, respectively.
*, **, ***P-value <.05, .01 and .001 compared with placebo treated group, respectively.
Effect of C. asiatica on physical fitness measured by hand grip.
| Hand strength | Pre-dose baseline score | Post-dose score | ||||
|---|---|---|---|---|---|---|
| 1 month | 2 month | 3 month | Delay | |||
| Left side (kg) | 23.65 ± 3.93 | 23.85 ± 4.33 | ||||
| Placebo | 23.05 ± 4.69 | 22.95 ± 4.57 | 23.48 ± 4.46 |
|
| |
|
|
| |||||
| 23.03 ± 6.19 | 22.20 ± 3.11 | |||||
| CA250 | 21.55 ± 3.45 | 22.28 ± 2.96 | 22.70 ± 2.34 |
|
| |
|
|
| |||||
| 23.25 ± 4.98 | ||||||
| 23.93 ± 5.64 |
| |||||
| CA500 | 24.80 ± 7.88 | 23.90 ± 6.59 | 22.98 ± 5.30 |
|
| |
|
| 24.80 ± 6.17 | |||||
| 25.75 ± 6.45 |
| |||||
| CA750 | 24.85 ± 6.29 | 25.50 ± 6.55 | 26.15 ± 7.30 |
|
| |
|
| ||||||
|
| ||||||
| Right side (kg) | 24.15 ± 5.09 | 23.95 ± 5.31 | ||||
| Placebo | 23.43 ± 5.63 | 23.33 ± 5.24 | 24.05 ± 5.44 |
|
| |
|
|
| |||||
| 23.35 ± 2.50 | ||||||
| 23.30 ± 3.11 |
| |||||
| CA250 | 23.40 ± 2.67 | 24.05 ± 3.78 | 23.38 ± 3.01 |
|
| |
|
| 24.00 ± 5.99 | |||||
| 25.93 ± 6.09 |
| |||||
| CA500 | 26.58 ± 7.95 | 24.7 ± 6.32 | 24.38 ± 5.16 |
|
| |
|
| 25.25 ± 6.34 | |||||
| 25.45 ± 5.27 |
| |||||
| CA750 | 26.18 ± 5.53 | 26.40 ± 5.44 | 26.98 ± 5.41 |
|
| |
|
| ||||||
Subjects were measured physical fitness by hand grip. Data are presented as mean ± SD. P- and F-values were compared between pre-dose baseline score and post-dose 1, 2, 3 month and 1 month after cessation of treatment (n = 20/group).
Effect of various doses of C. asiatica on the satisfaction physical fitness score which assessed using QOL questionnaire in healthy elderly volunteer.
| Aspect | Pre-dose baseline score | Post-dose | ||||
|---|---|---|---|---|---|---|
| 1 month | 2 month | 3 month | Delay | |||
| Physical Functioning | 80.00 ± 13.28 | |||||
| Placebo | 84.50 ± 11.96 | 82.00 ± 13.07 | 80.13 ± 9.68 | 79.00 ± 9.26 |
| |
|
| ||||||
| 80.50 ± 15.25 | ||||||
| CA250 | 78.25 ± 14.60 | 77.63 ± 16.13 | 80.75 ± 10.26 | 78.75 ± 12.13 |
| |
|
| ||||||
| 81.63 ± 13.01 | ||||||
| CA500 | 84.13 ± 11.59 | 82.88 ± 10.74 | 84.63 ± 10.86 | 86.00 ± 7.75* |
| |
|
| ||||||
| 80.50 ± 10.66 | ||||||
| CA750 | 78.89 ± 9.46 | 80.4 ± 9.9 | 82.88 ± 7.79b | 83.38 ± 7.53a |
| |
|
| ||||||
Subjects were measured the satisfaction score which assessed using QOL questionnaire. Data are presented as mean ± SD. P- and F-values were compared between pre-dose baseline score and post-dose score for 1, 2, 3 month and 1 month after the cessation of C. asiatica treatment (n = 20/group).
a, b P-value < .05 and .001 compared with pre-dose baseline score, respectively.
*P-value < .05 compared with placebo treated group.
Figure 1Effect of C. asiatica on the skeletal muscle of lower extremities. ROS: reactive oxygen species, O2: oxygen, LEs: lower extremities.